“For me, having lost my husband, it’s frustrating to hear publicly people saying to John McCain, ‘If anybody can beat this you can — you’re so tough.’ Not that it’s intentionally hurtful, but it does leave those of us who’ve lost a loved one thinking, ‘Was my loved one not tough enough? Did he not fight hard enough?'” ~Dannagal...
Read More
In a nutshell This study summarized findings on the treatment combination known as CRd (carfilzomib [Kyprolis], lenalidomide [Revlimid], and dexamethasone [Decadron]) for previously treated multiple myeloma. The study concluded that CRd is superior in improving progression and treatment response rates compared to available alternatives. Some...
Read More
In a nutshell This paper studied the use of carfilzomib (Kyprolis) in high-risk patients with multiple myeloma. This study concluded that carfilzomib improved survival and response to treatment. Some background Multiple myeloma is a cancer of the plasma cells (type of white blood cell). Following treatment, many patients relapse (have a...
Read More
In a nutshell This study analyzed the results of 13 separate studies on treatment combinations for multiple myeloma patients with the 17p deletion. This study concluded that bortezomib-based primary and maintenance therapy improved outcomes in newly diagnosed patients with the 17p deletion. The combination...
Read More
“I’m barely 27 and if it were not for immunotherapy and cancer research, I would not have seen 25.” So starts Stefanie Joho speech at a 2017 Congressional Hearing called “Progress in Immunotherapy: Delivering Hope and Clinical Benefit to Cancer Patients.” When Stefanie was 22, she was diagnosed with a very aggressive Stage II...
Read More
In a nutshell This study looked at how effective erythropoietin mouthwash was at preventing oral mucositis in cancer patients being treated with autologous stem cell transplantation. The study concluded that rinsing with erythropoietin mouthwash can prevent oral mucositis. Some background Oral mucositis (OM) is a complication associated with...
Read More
Video information: On location at the recent 2017 American Society of Clinical Oncology meeting (ASCO), Dr. Hearn Jay Cho of Mount Sinai Hospital discusses news out of ASCO 2017 and what it means for myeloma patients and care partners. Dr. Cho highlights news out of the meeting, including how experts are manipulating the immune system, precision...
Read MoreIn a nutshell This study reviewed evidence on the management of high-risk multiple myeloma. Some background Multiple myeloma is a diverse disease. Using predictors of treatment success is important to help select treatment approaches for patients. Higher risk patients may benefit from more aggressive treatment. There are multiple methods...
Read More
In a nutshell This study looked at how anxiety and depression influence the quality of life of patients with multiple myeloma. The study concluded that anxiety, depression, and unmet patient needs negatively impact the physical and emotional well-being of patients. Some background Multiple myeloma is a common type of cancer in older adults. The...
Read More
In a nutshell This phase 1 clinical trial will test the safety of isatuximab (SAR650984) in patients with relapsed or refractory multiple myeloma, as well as the effectiveness of isatuximab in multiple myeloma patients who have been previously treated with daratumumab (Darzalex). The primary outcome will be measured by side effects and overall...
Read More
In a nutshell This phase 1 clinical trial will test the safety of blinatumomab (Blincyto) treatment after high-dose melphalan (Alkeran) and autologous stem cell transplant in patients with refractory (unresponsive to treatment) multiple myeloma. The primary outcome will be measured by the number of adverse (negative) effects. The trial is being...
Read MoreIn a nutshell This phase 2 clinical trial will test the effectiveness of a high-dose BeEAM chemotherapy as a first-line treatment for multiple myeloma. The primary outcome will be measured by the response to the treatment. The details BeEAM is a combination chemotherapy containing 4 different drugs (bendamustine, etoposide, cytarabine, and...
Read More
